Acoramidis Is Favorable for Transthyretin Amyloid Cardiomyopathy

Acoramidis treatment compares favorably with tafamidis with respect to survival and reducing hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), according to a study being presented at the International Symposium on Amyloidosis, taking place May 26-30 in Rochester, Minnesota.

Tafamidis is currently the only approved treatment for ATTR-CM. However, recent data have shown that acoramidis can reduce cardiovascular-related hospitalizations (CVRH) compared with placebo. To date, no evidence has directly compared the 2 stabilizers.

In this retrospective, cohort study, researchers assessed 10 patients receiving acoramidis treatment for a median of 60 months and matched them (1:3) to a group of patients taking tafamidis (n=30) based on age, gender, race, genotype, and disease severity per Columbia score.

According to the results, there was a trend toward better survival for patients treated with acoramidis. Hierarchical analysis demonstrated a win ratio of 2.6 (range, 1.31-5.16) favoring acoramidis (P=.006), and hierarchical analysis in the matched cohort showed a win ratio of 1.88 (range, 0.74-4.77) in favor of acoramidis (P=.18).

“The present study, limited by a small sample size, showed for the first time that long-term treatment with acoramidis compares favorably [with] tafamidis in terms of survival and CVRH,” the researchers concluded.